Pub Date : 2016-10-18Epub Date: 2016-03-14DOI: 10.1503/cmaj.151081
Jodi T Bernstein, Mary R L'Abbé
{"title":"Added sugars on nutrition labels: a way to support population health in Canada.","authors":"Jodi T Bernstein, Mary R L'Abbé","doi":"10.1503/cmaj.151081","DOIUrl":"10.1503/cmaj.151081","url":null,"abstract":"","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"1 1","pages":"E373-E374"},"PeriodicalIF":14.6,"publicationDate":"2016-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89606585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-15DOI: 10.18553/JMCP.1999.5.1.52
W. Cantrell
OBJECTIVE: To compare blood pressure, serum creatinine, and serum potassium in stable patients before and after conversion from lisinopril to an equivalent dose of benazepril. DESIGN: A retrospective analysis of computer medical and pharmacy records during a one-year period, to obtain the last measured blood pressure, serum creatinine, and serum potassium obtained while patients were receiving lisinopril and again after conversion to benazepril. Certain measurements were excluded to decrease the influence of factors others than the angiotensin converting enzyme (ACE) inhibitors. SETTING: A Veterans Affairs Medical Center located in the western United States. PATIENTS: 687 patients were evaluated for blood pressure; 433 for serum creatinine; and 422 for serum potassium. The patients were predominantly elderly males. MAIN OUTCOME MEASURES: Measures of blood pressure, serum potassium and serum creatinine. RESULTS: No statistical difference was found for systolic blood pressure, diastolic blood pressure, or s...
{"title":"Evaluation of Blood Pressure and Adverse Effects in Patients Converted from Lisinopril to Benazepril","authors":"W. Cantrell","doi":"10.18553/JMCP.1999.5.1.52","DOIUrl":"https://doi.org/10.18553/JMCP.1999.5.1.52","url":null,"abstract":"OBJECTIVE: To compare blood pressure, serum creatinine, and serum potassium in stable patients before and after conversion from lisinopril to an equivalent dose of benazepril. DESIGN: A retrospective analysis of computer medical and pharmacy records during a one-year period, to obtain the last measured blood pressure, serum creatinine, and serum potassium obtained while patients were receiving lisinopril and again after conversion to benazepril. Certain measurements were excluded to decrease the influence of factors others than the angiotensin converting enzyme (ACE) inhibitors. SETTING: A Veterans Affairs Medical Center located in the western United States. PATIENTS: 687 patients were evaluated for blood pressure; 433 for serum creatinine; and 422 for serum potassium. The patients were predominantly elderly males. MAIN OUTCOME MEASURES: Measures of blood pressure, serum potassium and serum creatinine. RESULTS: No statistical difference was found for systolic blood pressure, diastolic blood pressure, or s...","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"123 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.18553/JMCP.1999.5.1.52","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67487642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-15DOI: 10.18553/jmcp.1999.5.5.382
L. Delaet
During the last 15 years, the number and type of managed care contracts has grown appreciably As health plans have struggled to meet the mandate to control costs, they have revamped old tools and applied them in new ways. One such technique involves phaffi1acy cost risk sharing with physician groups. Pharmacy risk sharing invites all P?rties to manage the pharmacy benefit jointly and share the positive or negative financial consequences. Long used in California, risk sharing is becoming more common in other parts of the country and has presented a new opportunity for pharmacists to apply their clinical and
{"title":"Managing Pharmacy Risk in Physician Groups","authors":"L. Delaet","doi":"10.18553/jmcp.1999.5.5.382","DOIUrl":"https://doi.org/10.18553/jmcp.1999.5.5.382","url":null,"abstract":"During the last 15 years, the number and type of managed care contracts has grown appreciably As health plans have struggled to meet the mandate to control costs, they have revamped old tools and applied them in new ways. One such technique involves phaffi1acy cost risk sharing with physician groups. Pharmacy risk sharing invites all P?rties to manage the pharmacy benefit jointly and share the positive or negative financial consequences. Long used in California, risk sharing is becoming more common in other parts of the country and has presented a new opportunity for pharmacists to apply their clinical and","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67488080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-15DOI: 10.18553/JMCP.1999.5.5.420
D. Scott
OBJECTIVE: To assess the willingness of insurance carriers to reimburse for pharmaceutical care and to determine the extent and success of the Pharmacist Care Claim Form (PCCF) used in obtaining reimbursement. DESIGN: A nine-item survey addressing the PCCF (compiled by the National Community Pharmacists Association, formerly the National Association of Retail druggists. Reimbursement was sent to a random sample of insurance carriers including Blue Cross/Blue Shield, health maintenance organizations (HMOs), preferred provider organizations (PPOs), and commercial insurance companies. RESULT: Overall, 116 of 311 (37.3%) surveys were returned (Blue Cross, 57.4%; HMOs, 41.6%; PPOs, 30.7%; and commercial carriers, 27.0%). Of insurance carriers, 6.9% of 116 respondents reported they had reimbursed pharmacists for nondispensing activities. Two carriers reported reimbursement for "monitoring of drug therapy" and "prescription counseling." Only two health insurance carriers reported reimbursement to pharmacists usi...
{"title":"Reimbursement for Pharmacy Cognitive Services: Pharmacists' Assessment","authors":"D. Scott","doi":"10.18553/JMCP.1999.5.5.420","DOIUrl":"https://doi.org/10.18553/JMCP.1999.5.5.420","url":null,"abstract":"OBJECTIVE: To assess the willingness of insurance carriers to reimburse for pharmaceutical care and to determine the extent and success of the Pharmacist Care Claim Form (PCCF) used in obtaining reimbursement. DESIGN: A nine-item survey addressing the PCCF (compiled by the National Community Pharmacists Association, formerly the National Association of Retail druggists. Reimbursement was sent to a random sample of insurance carriers including Blue Cross/Blue Shield, health maintenance organizations (HMOs), preferred provider organizations (PPOs), and commercial insurance companies. RESULT: Overall, 116 of 311 (37.3%) surveys were returned (Blue Cross, 57.4%; HMOs, 41.6%; PPOs, 30.7%; and commercial carriers, 27.0%). Of insurance carriers, 6.9% of 116 respondents reported they had reimbursed pharmacists for nondispensing activities. Two carriers reported reimbursement for \"monitoring of drug therapy\" and \"prescription counseling.\" Only two health insurance carriers reported reimbursement to pharmacists usi...","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67488144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-15DOI: 10.18553/JMCP.2001.7.1.43
W. Doucette
OBJECTIVES: To address the gaps in knowledge of pharmacies' evaluation of third-party contracts and the bargaining process between community pharmacies and third parties by: (1) assessing what activities pharmacies regularly perform in evaluating and signing a third-party contract; (2) determining which bargaining activities are occurring between pharmacies and third-party payors; and (3) evaluating the associations among the characteristics of the bargaining parties, the bargaining process, and bargaining outcomes with community pharmacies and third-party payors. DESIGN: Mail survey. PARTICIPANTS: A random sample of 900 independent and small-chain pharmacies. RESULTS: Ofthe 863 delivered surveys, 308 (35.7%) were returned and analyzed. Respondents did not report a high level of formal contract evaluation. They reported, on average, that they rarely requested a change in a contract. This was consistent with the finding that third parties usually refuse to negotiate changes in a contract. The respondents reported that sometimes they did not sign a contract because of unacceptable terms. Multiple regres~ sions for two bargaining outcomesequity of contractual terms and satisfaction with a third party payor-were significant. The same bargainer and bargaining process variables were used as the independent variables in the regressions. For equity of contractual terms (R Square=0.442), significant associations were found for contending, problem solving, and dependence symmetry. For satisfaction with a third-party payor (R Square=OA29), significant associations were found for collaborative communication, contending, and dependence symmetry. CONCLUSIONS: Pharmacies should develop strategies to improve communication with third parties. The symmetry of dependence between a pharmacy and a third-party payor is a key influence on bargaining outcomes. The strategies employed during bargaining, such as contending or problem solving, also affect bargaining outcomes.
{"title":"Bargaining Between Community Pharmacies and Third-Party Payors: Influences on Bargaining Outcomes","authors":"W. Doucette","doi":"10.18553/JMCP.2001.7.1.43","DOIUrl":"https://doi.org/10.18553/JMCP.2001.7.1.43","url":null,"abstract":"OBJECTIVES: To address the gaps in knowledge of pharmacies' evaluation of third-party contracts and the bargaining process between community pharmacies and third parties by: (1) assessing what activities pharmacies regularly perform in evaluating and signing a third-party contract; (2) determining which bargaining activities are occurring between pharmacies and third-party payors; and (3) evaluating the associations among the characteristics of the bargaining parties, the bargaining process, and bargaining outcomes with community pharmacies and third-party payors. DESIGN: Mail survey. PARTICIPANTS: A random sample of 900 independent and small-chain pharmacies. RESULTS: Ofthe 863 delivered surveys, 308 (35.7%) were returned and analyzed. Respondents did not report a high level of formal contract evaluation. They reported, on average, that they rarely requested a change in a contract. This was consistent with the finding that third parties usually refuse to negotiate changes in a contract. The respondents reported that sometimes they did not sign a contract because of unacceptable terms. Multiple regres~ sions for two bargaining outcomesequity of contractual terms and satisfaction with a third party payor-were significant. The same bargainer and bargaining process variables were used as the independent variables in the regressions. For equity of contractual terms (R Square=0.442), significant associations were found for contending, problem solving, and dependence symmetry. For satisfaction with a third-party payor (R Square=OA29), significant associations were found for collaborative communication, contending, and dependence symmetry. CONCLUSIONS: Pharmacies should develop strategies to improve communication with third parties. The symmetry of dependence between a pharmacy and a third-party payor is a key influence on bargaining outcomes. The strategies employed during bargaining, such as contending or problem solving, also affect bargaining outcomes.","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67489548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-15DOI: 10.18553/JMCP.2001.7.4.309
L. Norton
The second report of the Committee on the Quality of Health Care in America, Crossing the Quality Chasm: A New Health System for the 21st Century is currently available as an advanced copy (uncorrected proofs). It expands the committee's work beyond the focus on medical and medication error in To Err Is Human: Building a Safer Health System to a larger issue: the need to improve the quality of health care. 2 The new report outlines aims and principles for an improved design for the delivery of care. The text emphasizes that it is written not to present specifics but to present a new perspective on the purpose, intents, interactions, and processes of health care. The authors acknowledge that it will be necessary to redesign structures and processes of organizations and of professionals and their interactions. They also acknowledge that the practices of the nation's health care system, providers, and users must change to include improvements in dissemination and application of knowledge and potential advanc...
{"title":"A Prescription for Change: Bridges to Cross the Quality Chasm","authors":"L. Norton","doi":"10.18553/JMCP.2001.7.4.309","DOIUrl":"https://doi.org/10.18553/JMCP.2001.7.4.309","url":null,"abstract":"The second report of the Committee on the Quality of Health Care in America, Crossing the Quality Chasm: A New Health System for the 21st Century is currently available as an advanced copy (uncorrected proofs). It expands the committee's work beyond the focus on medical and medication error in To Err Is Human: Building a Safer Health System to a larger issue: the need to improve the quality of health care. 2 The new report outlines aims and principles for an improved design for the delivery of care. The text emphasizes that it is written not to present specifics but to present a new perspective on the purpose, intents, interactions, and processes of health care. The authors acknowledge that it will be necessary to redesign structures and processes of organizations and of professionals and their interactions. They also acknowledge that the practices of the nation's health care system, providers, and users must change to include improvements in dissemination and application of knowledge and potential advanc...","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67489723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-15DOI: 10.18553/jmcp.2001.7.5.349
J. Wick
ecent legislation revising the Occupational Safety and Health Administration’s (OSHA’s) regulations on preventing needle-stick injuries (NSI) became mandatory in April 2001 and impacts managed care providers and their members in interesting ways. The most immediate impact requires the consideration of the use of sharps that employ safety features; if alternatives to the use of sharps exist, these too should be employed. Say “occupational hazard” and most people will envision hard hats, safety glasses, and heavy industrial equipment. But carpal-tunnel syndrome and back strain have largely displaced mangled limbs as occupational hazards. Consequently, workplace hazards don’t seem as dangerous. Workers routinely develop healthy respect for certain tools, and circumstances command appropriate precautions. For health care workers, the hypodermic syringe is one such tool. Federal interventions address all types of sharps (any device that has a needle or sharp device attached to it). Syringes, however, are of most importance to managed care pharmacy. Certain questions arise regarding their use. Why are syringes and needles such a problem? In an era in which cost containment is an increasing challenge, what budget impact will new safety devices have? How will the switch to non-injectable alternatives affect the formulary or the multi-tiered payment structure? Will legislation, particularly at the state level, eventually extend to outpatient dispensing of syringes? Should these safety devices be covered for members who use injectable drugs at home now? Unquestionably, syringes and needles save lives and are a staple in our arsenal of medical devices, but we have known for decades that injury with a contaminated needle can transmit disease. For years, our main concern was hepatitis. Today, more than 20 blood-borne pathogens have been transmitted via a needlestick-related injury. Three are of particular concern: hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Table 1, page 350, describes the perils associated with each of these. In 1983, 17,000 workers acquired hepatitis B; today experts estimate that better work practices have reduced the number remarkably—to 800 annually. Better work practices, education, and personal protective equipment have successfully reduced transmission of all blood-borne pathogens over the past decades. They have, however, reached the limits of their efficacy. Changes in equipment design are now necessary to further decrease NSI.
{"title":"New Standards To Prevent Needle-stick Injury","authors":"J. Wick","doi":"10.18553/jmcp.2001.7.5.349","DOIUrl":"https://doi.org/10.18553/jmcp.2001.7.5.349","url":null,"abstract":"ecent legislation revising the Occupational Safety and Health Administration’s (OSHA’s) regulations on preventing needle-stick injuries (NSI) became mandatory in April 2001 and impacts managed care providers and their members in interesting ways. The most immediate impact requires the consideration of the use of sharps that employ safety features; if alternatives to the use of sharps exist, these too should be employed. Say “occupational hazard” and most people will envision hard hats, safety glasses, and heavy industrial equipment. But carpal-tunnel syndrome and back strain have largely displaced mangled limbs as occupational hazards. Consequently, workplace hazards don’t seem as dangerous. Workers routinely develop healthy respect for certain tools, and circumstances command appropriate precautions. For health care workers, the hypodermic syringe is one such tool. Federal interventions address all types of sharps (any device that has a needle or sharp device attached to it). Syringes, however, are of most importance to managed care pharmacy. Certain questions arise regarding their use. Why are syringes and needles such a problem? In an era in which cost containment is an increasing challenge, what budget impact will new safety devices have? How will the switch to non-injectable alternatives affect the formulary or the multi-tiered payment structure? Will legislation, particularly at the state level, eventually extend to outpatient dispensing of syringes? Should these safety devices be covered for members who use injectable drugs at home now? Unquestionably, syringes and needles save lives and are a staple in our arsenal of medical devices, but we have known for decades that injury with a contaminated needle can transmit disease. For years, our main concern was hepatitis. Today, more than 20 blood-borne pathogens have been transmitted via a needlestick-related injury. Three are of particular concern: hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Table 1, page 350, describes the perils associated with each of these. In 1983, 17,000 workers acquired hepatitis B; today experts estimate that better work practices have reduced the number remarkably—to 800 annually. Better work practices, education, and personal protective equipment have successfully reduced transmission of all blood-borne pathogens over the past decades. They have, however, reached the limits of their efficacy. Changes in equipment design are now necessary to further decrease NSI.","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67489888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-15DOI: 10.18553/JMCP.2001.7.3.224
G. Tucker, A. Moore, Deborah D. Avant, M. Monteiro
{"title":"A Cost Analysis of Four Benefit Strategies for Managing a Cox II Inhibitor","authors":"G. Tucker, A. Moore, Deborah D. Avant, M. Monteiro","doi":"10.18553/JMCP.2001.7.3.224","DOIUrl":"https://doi.org/10.18553/JMCP.2001.7.3.224","url":null,"abstract":"","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67489948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-15DOI: 10.18553/jmcp.2001.7.s2.4
W. Berge, G. Ledgerwood, O. Shoheiber, D. Giaquinta, E. Cannon
{"title":"An Etiology - Specific Diagnosis","authors":"W. Berge, G. Ledgerwood, O. Shoheiber, D. Giaquinta, E. Cannon","doi":"10.18553/jmcp.2001.7.s2.4","DOIUrl":"https://doi.org/10.18553/jmcp.2001.7.s2.4","url":null,"abstract":"","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-15DOI: 10.18553/JMCP.2001.7.6.482
Marcus C. Ravnan
Health care and health benefit providers are faced, now more than ever, with the increasing need to provide aggressive lipid management in an attempt to reduce cardiac-related morbidity and mortality and the associated human and system costs. Amid this growing need, we are faced with new challenges. The removal of a recently approved cholesterol-lowering drug (cerivastatin, Baycol by Bayer) from the market has raised doubts in the minds of Americans currently using the hydroxymethylglutaryl-coenzyme. A reductase inhibitors or so-called statins for cholesterol management. Compounding the problem, the media has highlighted the issue, and many patients now question the safety of other cholesterol-lowering medications. In addition, the release of the Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP), which builds on two previous cholesterol guidelines, expands the role of intensive cholesterol-lowering therapy in clinical practice. 1-3 Providers need to be well educate...
卫生保健和健康福利提供者现在比以往任何时候都更需要提供积极的脂质管理，以降低与心脏相关的发病率和死亡率以及相关的人力和系统成本。在这种日益增长的需求中，我们面临着新的挑战。最近批准的一种降胆固醇药物(cerivastatin, Baycol by Bayer)从市场上被撤下，这让目前使用羟甲基戊二酰辅酶的美国人产生了怀疑。一种用于控制胆固醇的还原酶抑制剂或他汀类药物。雪上加霜的是，媒体强调了这个问题，许多患者现在质疑其他降胆固醇药物的安全性。此外，国家胆固醇教育计划(NCEP)第三次报告执行摘要的发布，建立在之前的两个胆固醇指南的基础上，扩大了强化降胆固醇治疗在临床实践中的作用。1-3名供应商需要接受良好的教育……
{"title":"High Blood Cholesterol and ATP III: Guidelines for Health Benefit and Health Care Providers","authors":"Marcus C. Ravnan","doi":"10.18553/JMCP.2001.7.6.482","DOIUrl":"https://doi.org/10.18553/JMCP.2001.7.6.482","url":null,"abstract":"Health care and health benefit providers are faced, now more than ever, with the increasing need to provide aggressive lipid management in an attempt to reduce cardiac-related morbidity and mortality and the associated human and system costs. Amid this growing need, we are faced with new challenges. The removal of a recently approved cholesterol-lowering drug (cerivastatin, Baycol by Bayer) from the market has raised doubts in the minds of Americans currently using the hydroxymethylglutaryl-coenzyme. A reductase inhibitors or so-called statins for cholesterol management. Compounding the problem, the media has highlighted the issue, and many patients now question the safety of other cholesterol-lowering medications. In addition, the release of the Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP), which builds on two previous cholesterol guidelines, expands the role of intensive cholesterol-lowering therapy in clinical practice. 1-3 Providers need to be well educate...","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：